Calyx and Invicro are now Perceptive
Independent review of trial event assessments by adjudication experts.
Proven expertise in delivering high-quality imaging data at a global scale.
With strengths in instrument engineering, signal processing, and pharmaceutical R&D, Perceptive Discovery consistently delivers successful imaging study designs and executions.
Effective RTSM, built on 30 years of experience, and connected to an ecosystem which includes eConsent and eCOA.
Highly established imaging centers for first-in-human and multicenter trials.
900+ agents radiolabeled and counting.
Supporting both malignant and non-malignant indications.
Experts in Alzheimer’s Disease, Parkinson’s Disease imaging and more.
Supporting over 85% of radiopharmaceutical companies.
Optimize preclinical and clinical trials in other areas and drug classifications.
Therapeutic and technical expertise in imaging modalities, protocol design, and acquisition.
Oncology imaging, RTSM, and clinical adjudication services.
Tackling unique rare disease trial supply, imaging and adjudication challenges.
We are here to serve science.
From discovery, through early to late-phase clinical development, to regulatory approval and post-market, you can count on Perceptive to be dependable, diligent, and driven in everything we do.
Perceptive Discovery bridges preclinical insights to early clinical success, ensuring rigorous scientific analysis and high-quality data to support innovation.
Providing the right-fit randomization & trial supply management solution for your trials, delivered by experts.
The right people, experience, and technology to drive clinical trial imaging success.
Welcome to the forefront of Parkinson’s disease (PD) research! At Perceptive, we provide a comprehensive suite of imaging services dedicated to advancing PD research and therapy development.
Developing novel CNS therapies is a complex endeavor, requiring scientific rigor, medical expertise, and operational excellence. Our proven track record in supporting CNS Imaging studies reflects our commitment to transforming healthcare through innovative imaging and informatics.
Industry-Leading Tools for Neuro PET, SPECT, and MRI Analysis
While Parkinson’s disease remains a clinical diagnosis, imaging studies play a critical role in differential diagnosis and research. Techniques such as DaT SPECT scans confirm parkinsonism and differentiate PD from secondary motor symptoms. Emerging advanced imaging modalities promise new biomarkers for diagnosing and tracking disease progression.
Ongoing research explores PET and SPECT tracers targeting dopamine biosynthesis, serotonin and acetylcholine receptors, and cerebral pathological protein deposits. The development of an α-synuclein tracer – the pathologic hallmark of PD – would revolutionize PD research. PET and SPECT analysis coupled with MRI approaches will enable better understanding of the disease pathophysiology and treatment effects.
Our dedicated team of imaging experts and scientists combines scientific mastery with a deep understanding of Parkinson’s pathology to drive groundbreaking discoveries.
Teams with unparalleled knowledge in imaging, biomarker development, and preclinical models.
State-of-the-art imaging tools and bioinformatics capabilities.
Partnerships with academia, pharmaceutical companies, and research organizations.
Adherence to rigorous regulatory standards ensures reliable research data.
Choose Perceptive for unmatched expertise and cutting-edge technology to advance breakthroughs in PD research and therapy development.
Contact us today to discuss your specific needs and join us in forging new frontiers in Parkinson’s disease research.
Reach out today and one of our solution experts will be in touch to learn about your specific needs.
